Advances in virus-vectored vaccines

doi:10.12211/2096-8280.2023-063

Abstract

Abstract:

Recent outbreaks of infectious diseases, such as the middle east respiratory syndrome, Zika infection, Ebola hemorrhagic fever, and Coronavirus disease (COVID-19) pose significant challenges on the rapid development of efficacious vaccines. Virus-vectored vaccines, as an important new vaccine, can be administrated noninvasively through aerosol inhalation or oral administration, which could stimulate humoral, cellular, and mucosal immune responses without the need for adjuvants, showing good immunogenicity and safety in clinical trials or in emergency use. With the deeper understanding of the viral genome and structural proteins, synthetic biology has enabled the design and modification of viruses to produce recombinant viral vector-based vaccines with high titer, safety, and immunogenicity, and such research has significant implications for the vaccine development. This review highlights major strategies employed in the construction of virus-vectored vaccines, including the construction method of replication-competent or replication-defective viral vectors, and the development of viral vectors commonly used in producing the recombinant vaccines. Among these viral vectors, replication-deficient adenovirus-based vectors with gene deletion in the E1 and E3 regions are most mature for use. Currently, adenoviral vectors that have been used in the approved recombinant vaccines include Ad5, Ad26 and ChAdOx1. Vesicular stomatitis virus and flavivirus with small genomes are negative-sense and positive-sense single-stranded RNA viruses, respectively, which are easy to prepare and more suitable for being used in developing recombinant vaccines with small antigen proteins. Poxviruses and herpesviruses have large genomes for high packing capacity, but they are most difficult to be modified with synthetic biology methods. Different viral vectors need to be prepared using different strategies, and consequently vaccines developed with these vectors have different immune effects. The construction strategies of different viral vector vaccines introduced in this review will provide valuable theoretical reference for the research and development of novel viral vector vaccines. In the future, virus-vectored vaccines will be iteratively developed for higher safety, stronger protection, better compliance and lower production cost. {L-End}

Key words: viral vector, infectious disease, vaccine, synthetic biology, modification

摘要：

近十年来，中东呼吸综合征、埃博拉出血热、寨卡病毒感染、新型冠状病毒肺炎等重大传染性疾病疫情相继出现，对疫苗的快速研发提出重大挑战。其中病毒载体疫苗是新型疫苗研发的重要形式，它可以通过雾化吸入或口服等方式进行无创免疫，在没有佐剂的情况下发挥免疫作用，同时诱导体液、细胞和黏膜免疫反应，具有良好的免疫原性和安全性。随着对病毒基因组和结构蛋白等元件认识的不断深入，利用合成生物学研究思路系统设计、改造病毒载体，从而赋予重组病毒载体疫苗高滴度生产、高安全性和高免疫原性等生物学特征，对疫苗研发具有重要指导意义。本文综述了复制型、非复制型等病毒载体疫苗研发策略，以及具有临床应用价值的疫苗病毒载体，如腺病毒载体、痘病毒载体、水疱性口炎病毒载体等，希望对利用合成生物学进行新型病毒载体疫苗的研发提供一定的参考。未来，病毒载体疫苗必将向着更高的安全性、更强的保护性、更好的依从性、更低的生产成本等方向迭代发展。

关键词: 病毒载体, 传染病, 疫苗, 合成生物学, 改造

CLC Number:

R373

Busen WANG, Jinghan XU, Zhiqiang GAO, Lihua HOU. Advances in virus-vectored vaccines[J]. Synthetic Biology Journal, 2024, 5(2): 281-293.

王步森, 徐婧含, 高智强, 侯利华. 病毒载体疫苗研究进展[J]. 合成生物学, 2024, 5(2): 281-293.

Figures/Tables 2

Table 1 Major viral vectors used in vaccine development

病毒种类	基因组					主要型别
病毒种类	类型	长度/kb	容量/kb	是否入核	是否整合	主要型别
腺病毒	DNA	36	7～8	是	否	5型^[14]，35型^[15]，黑猩猩3型^[16]
痘病毒	DNA	170～300	25	否	否	痘苗安卡拉株^[17]，金丝雀痘病毒^[18]
水疱性口炎病毒	RNA	11	4.5	否	否	印第安纳株^[19]，新泽西株^[20]
黄病毒	RNA	10	2	否	否	黄热病毒^[21]，日本脑炎病毒^[22]
疱疹病毒	DNA	140～230	30	是	是	水痘-带状疱疹病毒^[2]，人单纯疱疹病毒^[23]

Fig. 1 Schematic diagrams for the genome structure of virus-vectored vaccines[(a) Genome structure of AdV-vectored vaccines. The E1 and E3 regions in the genome are all deleted, and the expression cassette can be inserted into the E1 deletion site by splicing in vitro. (b) Genome structure of MVA-based vaccines. The thymidine kinase (TK) in the genome is designed as site for gene insertion, and the expression cassette can be inserted by homologous recombination in the sensitive cells. (c) Genome structure of VSV-based vaccines. The glycoprotein of VSV can be replaced by the glycoprotein from other enveloped viruses. (d) Genome structure of YFV-based vaccines. The prM and E proteins in the YFV genome can be replaced by prM and E proteins from other flaviviruses. (e) Genome structure of HSV-based vaccines. The expression cassettes can be inserted into the UL or US regions in the viral genome.]

References 101

1	KATZ I T, WEINTRAUB R, BEKKER L G, et al. From vaccine nationalism to vaccine equity—finding a path forward[J]. The New England Journal of Medicine, 2021, 384(14): 1281-1283.
2	HEINEMAN T C, CONNELLY B L, BOURNE N, et al. Immunization with recombinant varicella-zoster virus expressing herpes simplex virus type 2 glycoprotein D reduces the severity of genital herpes in guinea pigs[J]. Journal of Virology, 1995, 69(12): 8109-8113.
3	CHEN M Y, BUTLER S S, CHEN W T, et al. Physical, chemical, and synthetic virology: reprogramming viruses as controllable nanodevices[J]. Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology, 2019, 11(3): e1545.
4	CAPEDING M R, ALBERTO E R, BOUCKENOOGHE A, et al. Five-year antibody persistence following a Japanese encephalitis chimeric virus vaccine (JE-CV) booster in JE-CV-primed children in the Philippines[J]. The Journal of Infectious Diseases, 2018, 217(4): 567-571.
5	GARBUTT M, LIEBSCHER R, WAHL-JENSEN V, et al. Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses[J]. Journal of Virology, 2004, 78(10): 5458-5465.
6	THAO T THI NHU, LABROUSSAA F, EBERT N, et al. Rapid reconstruction of SARS-CoV-2 using a synthetic genomics platform[J]. Nature, 2020, 582(7813): 561-565.
7	BRAUCHER D R, HENNINGSON J N, LOVING C L, et al. Intranasal vaccination with replication-defective adenovirus type 5 encoding influenza virus hemagglutinin elicits protective immunity to homologous challenge and partial protection to heterologous challenge in pigs[J]. Clinical and Vaccine Immunology, 2012, 19(11): 1722-1729.
8	BETT A J, HADDARA W, PREVEC L, et al. An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3[J]. Proceedings of the National Academy of Sciences of the United States of America, 1994, 91(19): 8802-8806.
9	CORVER J, LENCHES E, SMITH K, et al. Fine mapping of a cis-acting sequence element in yellow fever virus RNA that is required for RNA replication and cyclization[J]. Journal of Virology, 2003, 77(3): 2265-2270.
10	HILL-BATORSKI L, HATTA Y, MOSER M J, et al. Quadrivalent formulation of intranasal influenza vaccine M2SR (M2-deficient single replication) protects against drifted influenza A and B virus challenge[J]. Vaccines, 2023, 11(4): 798.
11	WONG G, RICHARDSON J S, CUTTS T, et al. Intranasal immunization with an adenovirus vaccine protects guinea pigs from Ebola virus transmission by infected animals[J]. Antiviral Research, 2015, 116: 17-19.
12	SINZGER C, EBERHARDT K, CAVIGNAC Y, et al. Macrophage cultures are susceptible to lytic productive infection by endothelial-cell-propagated human cytomegalovirus strains and present viral IE1 protein to CD4⁺ T cells despite late downregulation of MHC class Ⅱ molecules[J]. Journal of General Virology, 2006, 87(7): 1853-1862.
13	COOPER D, WRIGHT K J, CALDERON P C, et al. Attenuation of recombinant vesicular stomatitis virus-human immunodeficiency virus type 1 vaccine vectors by gene translocations and G gene truncation reduces neurovirulence and enhances immunogenicity in mice[J]. Journal of Virology, 2008, 82(1): 207-219.
14	ZHU F C, LI Y H, GUAN X H, et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial[J]. The Lancet, 2020, 395(10240): 1845-1854.
15	VAN ZYL-SMIT R N, ESMAIL A, BATEMAN M E, et al. Safety and immunogenicity of adenovirus 35 tuberculosis vaccine candidate in adults with active or previous tuberculosis. A randomized trial[J]. American Journal of Respiratory and Critical Care Medicine, 2017, 195(9): 1171-1180.
16	DE SANTIS O, AUDRAN R, POTHIN E, et al. Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a study[J]. The Lancet Infectious Diseases, 2016, 16(3): 311-320.
17	PITTMAN P R, HAHN M, LEE H S, et al. Phase 3 efficacy trial of modified vaccinia Ankara as a vaccine against smallpox[J]. The New England Journal of Medicine, 2019, 381(20): 1897-1908.
18	GRAY G E, BEKKER L G, LAHER F, et al. Vaccine efficacy of ALVAC-HIV and bivalent subtype C gp120-MF59 in adults[J]. The New England Journal of Medicine, 2021, 384(12): 1089-1100.
19	HUTTNER A, DAYER J A, YERLY S, et al. The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial[J]. The Lancet Infectious Diseases, 2015, 15(10): 1156-1166.
20	KIM G N, CHOI J A, WU K Y, et al. A vesicular stomatitis virus-based prime-boost vaccination strategy induces potent and protective neutralizing antibodies against SARS-CoV-2[J]. PLoS Pathogens, 2021, 17(12): e1010092.
21	MA J, YAKASS M B, JANSEN S, et al. Live-attenuated YF17D-vectored COVID-19 vaccine protects from lethal yellow fever virus infection in mouse and hamster models[J]. eBioMedicine, 2022, 83: 104240.
22	HU P S, CHEN X M, HUANG L H, et al. A highly pathogenic porcine reproductive and respiratory syndrome virus candidate vaccine based on Japanese encephalitis virus replicon system[J]. PeerJ, 2017, 5: e3514.
23	KAUGARS K, DARDICK J, DE OLIVEIRA A P, et al. A recombinant herpes virus expressing influenza hemagglutinin confers protection and induces antibody-dependent cellular cytotoxicity[J]. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118(34): e2110714118.
24	SUMIDA S M, TRUITT D M, LEMCKERT A A C, et al. Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein[J]. The Journal of Immunology, 2005, 174(11): 7179-7185.
25	WOHLFART C. Neutralization of adenoviruses: kinetics, stoichiometry, and mechanisms[J]. Journal of Virology, 1988, 62(7): 2321-2328.
26	ROBERTS D M, NANDA A, HAVENGA M J E, et al. Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity[J]. Nature, 2006, 441(7090): 239-243.
27	ABE S, OKUDA K, URA T, et al. Adenovirus type 5 with modified hexons induces robust transgene-specific immune responses in mice with pre-existing immunity against adenovirus type 5[J]. The Journal of Gene Medicine, 2009, 11(7): 570-579.
28	URA T, OKUDA K, SHIMADA M. Developments in viral vector-based vaccines[J]. Vaccines, 2014, 2(3): 624-641.
29	FUCHS J D, BART P A, FRAHM N, et al. Safety and immunogenicity of a recombinant adenovirus serotype 35-vectored HIV-1 vaccine in adenovirus serotype 5 seronegative and seropositive individuals[J]. Journal of AIDS & Clinical Research, 2015, 6(5): 461.
30	WALSH D S, OWIRA V, POLHEMUS M, et al. Adenovirus type 35-vectored tuberculosis vaccine has an acceptable safety and tolerability profile in healthy, BCG-vaccinated, QuantiFERON^®-TB Gold (+) Kenyan adults without evidence of tuberculosis[J]. Vaccine, 2016, 34(21): 2430-2436.
31	MILLIGAN I D, GIBANI M M, SEWELL R, et al. Safety and immunogenicity of novel adenovirus type 26- and modified vaccinia ankara-vectored Ebola vaccines: a randomized clinical trial [J]. JAMA, 2016, 315(15): 1610-1623.
32	GURWITH M, LOCK M, TAYLOR E M, et al. Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza: a randomised, double-blind, placebo-controlled, phase 1 study[J]. The Lancet Infectious Diseases, 2013, 13(3): 238-250.
33	VORBURGER S A, HUNT K K. Adenoviral gene therapy[J]. The Oncologist, 2002, 7(1): 46-59.
34	YANG T C, DAYBALL K, WAN Y H, et al. Detailed analysis of the CD8⁺ T-cell response following adenovirus vaccination[J]. Journal of Virology, 2003, 77(24): 13407-13411.
35	HIWASA K, NAGAYA H, TERAO S J, et al. Improved gene transfer into bladder cancer cells using adenovirus vector containing RGD motif[J]. Anticancer Research, 2012, 32(8): 3137-3140.
36	XIN K Q, JOUNAI N, SOMEYA K, et al. Prime-boost vaccination with plasmid DNA and a chimeric adenovirus type 5 vector with type 35 fiber induces protective immunity against HIV[J]. Gene Therapy, 2005, 12(24): 1769-1777.
37	FOUGEROUX C, HOLST P. Future prospects for the development of cost-effective adenovirus vaccines[J]. International Journal of Molecular Sciences, 2017, 18(4): 686.
38	DEAL C, PEKOSZ A, KETNER G. Prospects for oral replicating adenovirus-vectored vaccines[J]. Vaccine, 2013, 31(32): 3236-3243.
39	CROSBY C M, BARRY M A. Ⅲa deleted adenovirus as a single-cycle genome replicating vector[J]. Virology, 2014, 462/463: 158-165.
40	CROSBY C M, MATCHETT W E, ANGUIANO-ZARATE S S, et al. Replicating single-cycle adenovirus vectors generate amplified influenza vaccine responses[J]. Journal of Virology, 2017, 91(2): e00720-16.
41	CROSBY C M, NEHETE P, SASTRY K J, et al. Amplified and persistent immune responses generated by single-cycle replicating adenovirus vaccines[J]. Journal of Virology, 2015, 89(1): 669-675.
42	ZYGRAICH N, LOBMANN M, PEETERMANS J, et al. Local and systemic response after simultaneous intranasal inoculation of temperature-sensitive mutants of parainfluenza 3, IBR and bovine adenovirus 3[J]. Developments in Biological Standardization, 1975, 28: 482-488.
43	CHENG T, SONG Y F, ZHANG Y, et al. A novel oncolytic adenovirus based on simian adenovirus serotype 24[J]. Oncotarget, 2017, 8(16): 26871-26885.
44	FOLEGATTI P M, EWER K J, ALEY P K, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial[J]. The Lancet, 2020, 396(10249): 467-478.
45	KAUFMANN J K, NETTELBECK D M. Virus chimeras for gene therapy, vaccination, and oncolysis: adenoviruses and beyond[J]. Trends in Molecular Medicine, 2012, 18(7): 365-376.
46	KAUFMAN H L, KOHLHAPP F J, ZLOZA A. Oncolytic viruses: a new class of immunotherapy drugs[J]. Nature Reviews Drug Discovery, 2015. 14(9): 642-662.
47	LI J X, HOU L H, MENG F Y, et al. Immunity duration of a recombinant adenovirus type-5 vector-based Ebola vaccine and a homologous prime-boost immunisation in healthy adults in China: final report of a randomised, double-blind, placebo-controlled, phase 1 trial[J]. The Lancet Global Health, 2017, 5(3): e324-e334.
48	ZHU F C, WURIE A H, HOU L H, et al. Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-centre, randomised, double-blind, placebo-controlled, phase 2 trial[J]. The Lancet, 2017, 389(10069): 621-628.
49	KENNEDY S B, BOLAY F, KIEH M, et al. Phase 2 placebo-controlled trial of two vaccines to prevent Ebola in Liberia[J]. New England Journal of Medicine, 2017, 377(15): 1438-1447.
50	MACKETT M, SMITH G L, MOSS B. Vaccinia virus: a selectable eukaryotic cloning and expression vector[J]. Proceedings of the National Academy of Sciences of the United States of America, 1982, 79(23): 7415-7419.
51	HOLGADO M P, FALIVENE J, MAETO C, et al. Deletion of A44L, A46R and C12L vaccinia virus genes from the MVA genome improved the vector immunogenicity by modifying the innate immune response generating enhanced and optimized specific T-cell responses[J]. Viruses, 2016, 8(5): 139.
52	VIEIRA GOMES A, SOUZA CARMO T, SILVA CARVALHO L, et al. Comparison of yeasts as hosts for recombinant protein production[J]. Microorganisms, 2018, 6(2): 38.
53	TAO Q Z, ZHANG H B. Cloning and stable maintenance of DNA fragments over 300 kb in Escherichia coli with conventional plasmid-based vectors[J]. Nucleic Acids Research, 1998, 26(21): 4901-4909.
54	DAVISON A J, MOSS B. New vaccinia virus recombination plasmids incorporating a synthetic late promoter for high level expression of foreign proteins[J]. Nucleic Acids Research, 1990, 18(14): 4285.
55	FALIVENE J, DEL MÉDICO ZAJAC M P, PASCUTTI M F, et al. Improving the MVA vaccine potential by deleting the viral gene coding for the IL-18 binding protein[J]. PLoS One, 2012, 7(2): e32220.
56	STICKL H, HOCHSTEIN-MINTZEL V, MAYR A, et al. MVA-Stufenimpfung gegen pocken: klinische erprobung des attenuierten pocken-lebendimpfstoffes, stamm MVA[J/OL]. Deutsche Medizinische Wochenschrift, 1974, 99(47): 2386-2392[2023-09-01]. .
57	GOMEZ C E, NAJERA J L, KRUPA M, et al. MVA and NYVAC as vaccines against emergent infectious diseases and cancer[J]. Current Gene Therapy, 2011, 11(3): 189-217.
58	DREXLER I, STAIB C, SUTTER G. Modified vaccinia virus Ankara as antigen delivery system: how can we best use its potential?[J]. Current Opinion in Biotechnology, 2004, 15(6): 506-512.
59	ZHU J G, MARTINEZ J, HUANG X P, et al. Innate immunity against vaccinia virus is mediated by TLR2 and requires TLR-independent production of IFN-Β[J]. Blood, 2007, 109(2): 619-625.
60	PRICE P J R, TORRES-DOMÍNGUEZ L E, BRANDMÜLLER C, et al. Modified vaccinia virus Ankara: innate immune activation and induction of cellular signalling[J]. Vaccine, 2013, 31(39): 4231-4234.
61	JORDAN I, NORTHOFF S, THIELE M, et al. A chemically defined production process for highly attenuated poxviruses[J]. Biologicals, 2011, 39(1): 50-58.
62	COONEY E. Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein[J]. The Lancet, 1991, 337(8741): 567-572.
63	GÓMEZ C E, NÁJERA J L, PERDIGUERO B, et al. The HIV/AIDS vaccine candidate MVA-B administered as a single immunogen in humans triggers robust, polyfunctional, and selective effector memory T cell responses to HIV-1 antigens[J]. Journal of Virology, 2011, 85(21): 11468-11478.
64	GARCÍA F, BERNALDO DE QUIRÓS J C L, GÓMEZ C E, et al. Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: a phase I clinical trial (RISVAC02)[J]. Vaccine, 2011, 29(46): 8309-8316.
65	BAKARI M, ABOUD S, NILSSON C, et al. Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania[J]. Vaccine, 2011, 29(46): 8417-8428.
66	CAVENAUGH J S, AWI D, MENDY M, et al. Partially randomized, non-blinded trial of DNA and MVA therapeutic vaccines based on hepatitis B virus surface protein for chronic HBV infection[J]. PLoS One, 2011, 6(2): e14626.
67	BERTHOUD T K, HAMILL M, LILLIE P J, et al. Potent CD8⁺ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1[J]. Clinical Infectious Diseases, 2011, 52(1): 1-7.
68	BEJON P, OGADA E, MWANGI T, et al. Extended follow-up following a phase 2b randomized trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya[J]. PLoS One, 2007, 2(8): e707.
69	TAMERIS M D, HATHERILL M, LANDRY B S, et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial[J]. The Lancet, 2013, 381(9871): 1021-1028.
70	TAPIA M D, SOW S O, LYKE K E, et al. Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial[J]. The Lancet Infectious Diseases, 2016, 16(1): 31-42.
71	EWER K, RAMPLING T, VENKATRAMAN N, et al. A monovalent chimpanzee adenovirus Ebola vaccine boosted with MVA[J]. The New England Journal of Medicine, 2016, 374(17): 1635-1646.
72	CHAN W M, RAHMAN M M, MCFADDEN G. Oncolytic myxoma virus: the path to clinic[J]. Vaccine, 2013, 31(39): 4252-4258.
73	GILBERT S C. Clinical development of Modified Vaccinia virus Ankara vaccines[J]. Vaccine, 2013, 31(39): 4241-4246.
74	ANTOINE G, SCHEIFLINGER F, DORNER F, et al. The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses[J]. Virology, 1998, 244(2): 365-396.
75	OVERTON E T, LAWRENCE S J, WAGNER E, et al. Immunogenicity and safety of three consecutive production lots of the non replicating smallpox vaccine MVA: a randomised, double blind, placebo controlled phase III trial[J]. PLoS One, 2018, 13(4): e0195897.
76	COSMA A, NAGARAJ R, BÜHLER S, et al. Therapeutic vaccination with MVA-HIV-1 nef elicits Nef-specific T-helper cell responses in chronically HIV-1 infected individuals[J]. Vaccine, 2003, 22(1): 21-29.
77	SAMY N, REICHHARDT D, SCHMIDT D, et al. Safety and immunogenicity of novel modified vaccinia Ankara-vectored RSV vaccine: a randomized phase Ⅰ clinical trial[J]. Vaccine, 2020, 38(11): 2608-2619.
78	JOHNSON J E, NASAR F, COLEMAN J W, et al. Neurovirulence properties of recombinant vesicular stomatitis virus vectors in non-human primates[J]. Virology, 2007, 360(1): 36-49.
79	SUN G Y, FANG X K, WU H, et al. Porcine monocyte-derived dendritic cells can be differentially activated by vesicular stomatitis virus and its matrix protein mutants[J]. Veterinary Microbiology, 2018, 219: 30-39.
80	RAUCH S, JASNY E, SCHMIDT K E, et al. New vaccine technologies to combat outbreak situations[J]. Frontiers in Immunology, 2018, 9: 1963.
81	FUCHS J D, FRANK I, ELIZAGA M L, et al. First-in-human evaluation of the safety and immunogenicity of a recombinant vesicular stomatitis virus human immunodeficiency virus-1 gag vaccine (HVTN 090)[J]. Open Forum Infectious Diseases, 2015, 2(3): ofv082.
82	AGNANDJI S T, HUTTNER A, ZINSER M E, et al. Phase 1 trials of rVSV Ebola vaccine in Africa and Europe[J]. The New England Journal of Medicine, 2016, 374(17): 1647-1660.
83	WONG G, MENDOZA E J, PLUMMER F A, et al. From bench to almost bedside: the long road to a licensed Ebola virus vaccine[J]. Expert Opinion on Biological Therapy, 2018, 18(2): 159-173.
84	ROBERTS A, BUONOCORE L, PRICE R, et al. Attenuated vesicular stomatitis viruses as vaccine vectors[J]. Journal of Virology, 1999, 73(5): 3723-3732.
85	EZELLE H J, MARKOVIC D, BARBER G N. Generation of hepatitis C virus-like particles by use of a recombinant vesicular stomatitis virus vector[J]. Journal of Virology, 2002, 76(23): 12325-12334.
86	KAHN J S, ROBERTS A, WEIBEL C, et al. Replication-competent or attenuated, nonpropagating vesicular stomatitis viruses expressing respiratory syncytial virus (RSV) antigens protect mice against RSV challenge[J]. Journal of Virology, 2001, 75(22): 11079-11087.
87	GEISBERT T W, JONES S, FRITZ E A, et al. Development of a new vaccine for the prevention of Lassa fever[J]. PLoS Medicine, 2005, 2(6): e183.
88	HERD K A, HARVEY T, KHROMYKH A A, et al. Recombinant Kunjin virus replicon vaccines induce protective T-cell immunity against human papillomavirus 16 E7-expressing tumour[J]. Virology, 2004, 319(2): 237-248.
89	THEILER M, SMITH H H. The use of yellow fever virus modified by in vitro cultivation for human immunization[J]. Reviews in Medical Virology, 2000, 10(1): 3-16.
90	MONATH T P, SELIGMAN S J, ROBERTSON J S, et al. Live virus vaccines based on a yellow fever vaccine backbone: standardized template with key considerations for a risk/benefit assessment[J]. Vaccine, 2015, 33(1): 62-72.
91	RECKER M, BLYUSS K B, SIMMONS C P, et al. Immunological serotype interactions and their effect on the epidemiological pattern of dengue[J]. Proceedings of the Royal Society B: Biological Sciences, 2009, 276(1667): 2541-2548.
92	YUN S I, LEE Y M. Japanese encephalitis: the virus and vaccines[J]. Human Vaccines & Immunotherapeutics, 2014, 10(2): 263-279.
93	LI E, GUO J, OH S J, et al. Anterograde transneuronal tracing and genetic control with engineered yellow fever vaccine YFV-17D[J]. Nature Methods, 2021, 18(12): 1542-1551.
94	MONATH T P, LIU J, KANESA-THASAN N, et al. A live, attenuated recombinant West Nile virus vaccine[J]. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103(17): 6694-6699.
95	XIAO H, HU H R, GUO Y J, et al. Construction and characterization of a synthesized herpes simplex virus H129-Syn-G2[J]. Virologica Sinica, 2023, 38(3): 373-379.
96	KAMIYAMA T, SATO H, TAKAHARA T, et al. Novel immunogenicity of Oka varicella vaccine vector expressing hepatitis B surface antigen[J]. The Journal of Infectious Diseases, 2000, 181(3): 1158-1161.
97	KAUR A, SANFORD H B, GARRY D, et al. Ability of herpes simplex virus vectors to boost immune responses to DNA vectors and to protect against challenge by simian immunodeficiency virus[J]. Virology, 2007, 357(2): 199-214.
98	TAYLOR T J, DIAZ F, COLGROVE R C, et al. Production of immunogenic West Nile virus-like particles using a herpes simplex virus 1 recombinant vector[J]. Virology, 2016, 496: 186-193.
99	CHESNEY J, AWASTHI S, CURTI B, et al. Phase Ⅲb safety results from an expanded-access protocol of talimogene laherparepvec for patients with unresected, stage ⅢB-ⅣM1c melanoma[J]. Melanoma Research, 2018, 28(1): 44-51.
100	TULMAN E R, DELHON G, AFONSO C L, et al. Genome of horsepox virus[J]. Journal of Virology, 2006, 80(18): 9244-9258.
101	NOYCE R S, LEDERMAN S, EVANS D H. Construction of an infectious horsepox virus vaccine from chemically synthesized DNA fragments[J]. PLoS One, 2018, 13(1): e0188453.

[1]	Huang XIE, Yilei ZHENG, Yiting SU, Jingyi RUAN, Yongquan LI. An overview on reconstructing the biosynthetic system of actinomycetes for polyketides production [J]. Synthetic Biology Journal, 2024, 5(3): 612-630.
[2]	Wenlong ZHA, Lan BU, Jiachen ZI. Advances in synthetic biology for producing potent pharmaceutical ingredients of traditional Chinese medicine [J]. Synthetic Biology Journal, 2024, 5(3): 631-657.
[3]	Zhen HUI, Xiaoyu TANG. Applications of the CRISPR/Cas9 editing system in the study of microbial natural products [J]. Synthetic Biology Journal, 2024, 5(3): 658-671.
[4]	Xiaonan LIU, Jing LI, Xiaoxi ZHU, Zishuo XU, Jian QI, Huifeng JIANG. Research advances on paclitaxel biosynthesis [J]. Synthetic Biology Journal, 2024, 5(3): 527-547.
[5]	Jingqin YE, Wenhua HUANG, Chao PAN, Li ZHU, Hengliang WANG. Applications of synthetic biology in developing polysaccharide conjugate vaccines [J]. Synthetic Biology Journal, 2024, 5(2): 338-352.
[6]	Xuejing MA, Chang GUO, Zhaolin HUA, Baidong HOU. Dawn of the rational design of nanoparticle vaccines aided by the advance of synthetic biology techniques [J]. Synthetic Biology Journal, 2024, 5(2): 353-368.
[7]	Zezhong LIU, Jie ZHOU, Yun ZHU, Lu LU, Shibo JIANG. Applications of the recombinant human collagen type Ⅲ-based trimerization motif in the design of vaccines to fight against SARS-CoV-2 and influenza virus [J]. Synthetic Biology Journal, 2024, 5(2): 385-395.
[8]	Huiyang TU, Weidong HAN, Bin ZHANG. Strategies for the design and optimization of tumor neoantigen vaccines [J]. Synthetic Biology Journal, 2024, 5(2): 254-266.
[9]	Zibin TAN, Kang LIANG, Youhai CHEN. Applications of synthetic biology in developing microbial-vectored cancer vaccines [J]. Synthetic Biology Journal, 2024, 5(2): 221-238.
[10]	Chao FANG, Weiren HUANG. Progress with the application of synthetic biology in designing of cancer vaccines [J]. Synthetic Biology Journal, 2024, 5(2): 239-253.
[11]	Xiya GUO, Ji CHEN, Mingxin DONG. New strategies for engineering influenza viruses and their applications [J]. Synthetic Biology Journal, 2024, 5(2): 267-280.
[12]	Shasha JIANG, Chen WANG, Ran LU, Fengjun LIU, Jun LI, Bin WANG. Applications of vector vaccines developed through T-cell immune responses in preventing and treating human diseases [J]. Synthetic Biology Journal, 2024, 5(2): 294-309.
[13]	Qing YE, Chengfeng QIN. Development of mRNA vaccines in response to the Public Health Emergency of International Concern [J]. Synthetic Biology Journal, 2024, 5(2): 310-320.
[14]	Jinyong ZHANG, Jiang GU, Shan GUAN, Haibo LI, Hao ZENG, Quanming ZOU. Synthetic biology promotes the development of bacterial vaccines [J]. Synthetic Biology Journal, 2024, 5(2): 321-337.
[15]	Weifeng YUAN, Yongliang ZHAO, Zhixuan WU, Ke XU. Applications of synthetic biology in the development of SARS-CoV-2 broad-spectrum vaccines [J]. Synthetic Biology Journal, 2024, 5(2): 369-384.